VYNE Therapeutics
- Pharmaceutical Preparations
- Bridgewater, New Jersey
Compensation history
Top executives at VYNE Therapeutics received an average of $2M per person in annual compensation from 2017 to 2023.
By year
Executives
We found eight executives who work or worked at VYNE Therapeutics.
David Domzalski
VYNE Therapeutics
Chief Executive Officer
Iain Stuart
VYNE Therapeutics
Chief Scientific Officer
Mutya Harsch
VYNE Therapeutics
Chief Legal Officer
Steven Basta
VYNE Therapeutics
Chief Executive Officer
Andrew Saik
VYNE Therapeutics
Chief Financial Officer
Kristine Ball
VYNE Therapeutics
Chief Financial Officer
Paul Kwon
VYNE Therapeutics
Chief Scientific Officer
Mary Spellman
VYNE Therapeutics
Chief Medical Officer
News
VYNE Therapeutics CEO David Domzalski's 2023 pay jumps 110% to $2.7M
November 12, 2024
VYNE Therapeutics CEO David Domzalski's 2022 pay falls 73% to $1.3M
November 13, 2023
VYNE Therapeutics CEO David Domzalski's 2021 pay jumps 69% to $4.9M
June 17, 2022
VYNE Therapeutics CEO David Domzalski receives $2.9M in 2020
June 7, 2021
VYNE Therapeutics CEO Steven Basta's 2019 pay falls 28% to $1.9M
June 22, 2020
VYNE Therapeutics CEO Steven Basta's 2018 pay jumps 156% to $2.6M
May 10, 2019
About VYNE Therapeutics
- Industry classifications
- Manufacturing
- Chemicals And Allied Products
- Drugs
- Pharmaceutical Preparations
- 685 Route 202/206 N., Suite 301, Bridgewater, New Jersey 08807
- 800-775-7936
- December 31
- Former names
- Menlo Therapeutics Inc.
- Menlo Therapeutics, Inc.
- Tigercat Pharma, Inc.